


MEDICINAL PRODUCTS 2021



ARCA biopharma Inc. Rank 7 of 52





MEDICINAL PRODUCTS 2021



ARCA biopharma Inc. Rank 7 of 52

The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 130% points. The greatest weakness of ARCA biopharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 110%, being 165% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	49,968
Assets, Non-Current	440
General and Administrative Expense	4,774
Goodwill	0
Liabilities, Current	3,499
Liabilities, Non-Current	409
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	28
Property, Plant and Equipment, Net	21
Research and Development	4,992

Output Variable	Value in 1000 USD
Liabilities	3,908
Assets	50,429
Expenses	9,766
Revenues	28
Stockholders Equity	46,521
Net Income	-9,738
Comprehensive Net Income	-9,738
Economic Capital Ratio	110%

